OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients.
Fiche publication
Date publication
janvier 2022
Journal
BMC cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle, Dr BERTAUT Aurélie, Dr BOIDOT Romain, Dr GENNE Philippe, Dr GOBBO Jessica, Dr DESMOULINS Isabelle
Tous les auteurs :
Vachenc S, Gobbo J, Moujarrebe SE, Desmoulins I, Gilabert M, Beau-Faller M, Mitry E, Girard N, Bertaut A, Dusetti N, Iovanna JL, Yousfi R, Pierrat F, Bruno R, Cueff A, Boidot R, Genne P
Lien Pubmed
Résumé
Nowadays, evaluation of the efficacy and the duration of treatment, in context of monitoring patients with solid tumors, is based on the RECIST methodology. With these criteria, resistance and/or insensitivity are defined as tumor non-response which does not allow a good understanding of the diversity of the underlying mechanisms. The main objective of the OncoSNIPE® collaborative clinical research program is to identify early and late markers of resistance to treatment.
Mots clés
Early/ late resistance marker, Immunological profile, NGS, Non small-cell lung cancer, Pancreatic ductal adenocarcinoma, Triple negative breast or Luminal Breast Cancer
Référence
BMC Cancer. 2022 Jan 6;22(1):41